Residency · Residency · Chronic Pain Management

Muscle Relaxants and Antispasmodics

Introduction

Skeletal muscle relaxants comprise a heterogeneous group of medications used for musculoskeletal pain with spasm and spasticity from upper motor neuron lesions. Despite their widespread prescription — over 30 million prescriptions annually in the United States — evidence for chronic use is limited, and the class harbors significant differences in mechanisms, efficacy, and safety. This lecture reviews baclofen, tizanidine, cyclobenzaprine, methocarbamol, and the abuse potential of carisoprodol.

Classification

Skeletal muscle relaxants fall into two broad categories, and this distinction is clinically important because agents from one group should not be substituted for those in the other.

Antispasticity agents treat velocity-dependent increased muscle tone from upper motor neuron pathology such as multiple sclerosis, spinal cord injury, and stroke. This group includes baclofen, tizanidine, and dantrolene. Antispasmodic agents, by contrast, treat acute musculoskeletal spasm and pain associated with peripheral musculoskeletal conditions. This group includes cyclobenzaprine, methocarbamol, metaxalone, carisoprodol, and orphenadrine.

<image>Classification diagram of skeletal muscle relaxants organized into two main branches — antispasticity agents and antispasmodic agents — with each drug listed under its category alongside its primary mechanism of action, showing baclofen (GABA-B agonist), tizanidine (alpha-2 agonist), dantrolene (ryanodine receptor), cyclobenzaprine (central acting, structurally related to TCAs), methocarbamol (central sedation), and carisoprodol (meprobamate metabolite, GABA-A), with arrows indicating site of action from spinal cord to muscle fiber</image>

Baclofen

Mechanism

Baclofen is a GABA-B receptor agonist that acts at both presynaptic and postsynaptic sites in the spinal cord. Presynaptic inhibition reduces excitatory neurotransmitter release (glutamate and aspartate), while postsynaptic hyperpolarization reduces motor neuron excitability. The net effect is a reduction in both polysynaptic and monosynaptic reflex activity.

Evidence and Indications

Baclofen is the first-line oral agent for spasticity from spinal cord injury and multiple sclerosis, with moderate evidence for spasticity-related pain reduction. For severe, refractory spasticity, intrathecal baclofen (ITB) delivered via an implantable pump is highly effective. Evidence for chronic musculoskeletal pain without spasticity is limited. Off-label uses include trigeminal neuralgia and alcohol use disorder.

Dosing

Oral dosing begins at 5 mg three times daily, titrating by 5 mg per dose every 3-5 days to a target of 40-80 mg per day in divided doses (maximum 80 mg per day orally). Intrathecal dosing typically ranges from 50 to 1000 mcg per day via a programmable pump. Renal dose adjustment is required because baclofen is primarily renally excreted.

Safety Considerations

The most critical safety issue with baclofen is that abrupt withdrawal can be life-threatening, producing seizures, hallucinations, hyperthermia, rhabdomyolysis, and autonomic instability. This is especially dangerous with intrathecal baclofen, where pump malfunction or catheter problems can precipitate sudden withdrawal. CNS depression manifesting as sedation, confusion, and dizziness is common. Baclofen also lowers the seizure threshold. When discontinuing, a gradual taper over 1-2 weeks minimum is mandatory.

Tizanidine

Mechanism

Tizanidine is a central alpha-2 adrenergic agonist that acts in the spinal cord and brainstem. It reduces excitatory amino acid release from spinal interneurons through a mechanism analogous to clonidine but with greater selectivity for the spinal cord. It reduces polysynaptic reflex activity with less effect on monosynaptic reflexes than baclofen.

Evidence and Indications

Tizanidine is FDA-approved for spasticity management in MS, spinal cord injury, and stroke. Evidence also supports its use in chronic myofascial pain and tension-type headache. Its antispasticity efficacy is comparable to baclofen and diazepam but with potentially less motor weakness. Tizanidine may have independent analgesic properties through alpha-2 mediated modulation of descending inhibitory pathways.

Dosing

Dosing begins at 2 mg at bedtime because initial doses produce significant sedation. The dose is titrated by 2-4 mg every 3-7 days to a target of 8-24 mg per day in divided doses (maximum 36 mg per day). Its short half-life (2.5 hours) necessitates three- to four-times-daily dosing for daytime spasticity management.

Safety Considerations

Hepatotoxicity is a notable risk — liver function tests should be monitored at baseline and at 1, 3, and 6 months, with the drug discontinued if ALT rises above three times the upper limit of normal. Significant sedation and dry mouth are common alpha-2 effects. Hypotension is additive with antihypertensives and requires blood pressure monitoring. A critical drug interaction exists with CYP1A2 metabolism: potent inhibitors such as fluvoxamine and ciprofloxacin dramatically increase tizanidine levels, and concurrent use with fluvoxamine is contraindicated. Rebound hypertension can occur with abrupt discontinuation.

Cyclobenzaprine

Mechanism

Cyclobenzaprine is structurally related to tricyclic antidepressants — it differs from amitriptyline by only one double bond. It acts centrally at the brainstem to reduce tonic somatic motor activity, reducing muscle spasm through effects on gamma and alpha motor neurons. It does not act directly at the neuromuscular junction or on muscle fibers. Like TCAs, it possesses anticholinergic, antihistaminic, and sedative properties.

Evidence and Indications

Cyclobenzaprine is FDA-approved for acute musculoskeletal spasm, recommended for a maximum of 2-3 weeks. Its NNT is approximately 5 for acute musculoskeletal conditions. Evidence for chronic use beyond 2-3 weeks is limited. Some evidence supports off-label use in fibromyalgia at low doses, where it may improve sleep quality. It is not effective for spasticity from upper motor neuron lesions.

Dosing

Standard dosing is 5-10 mg three times daily, starting at 5 mg for tolerability. An extended-release formulation allows 15-30 mg once daily. For fibromyalgia, very low doses of 1-4 mg at bedtime are used off-label. The long half-life (18-33 hours) means steady state is not reached for several days. Cyclobenzaprine is not recommended in patients over 65 due to anticholinergic burden.

Safety Considerations

Anticholinergic effects include dry mouth, constipation, urinary retention, and blurred vision. Sedation is the most common adverse effect, and patients should be advised against driving. Cyclobenzaprine is on the Beers Criteria list for potentially inappropriate medications in the elderly. Serotonin syndrome risk exists when combined with serotonergic medications. QT prolongation risk is similar to TCAs, making it unsuitable for patients with cardiac conduction disease. While not a controlled substance, it has abuse potential when combined with other CNS depressants.

<image>Comparative pharmacology table presented as an infographic showing baclofen, tizanidine, cyclobenzaprine, and methocarbamol in parallel columns, each displaying mechanism of action, FDA-approved indications, typical dose range, half-life, key metabolic pathway, most significant adverse effects, monitoring requirements, and a color-coded abuse potential rating from low (green) to high (red)</image>

Methocarbamol

Mechanism and Evidence

Methocarbamol is a central-acting muscle relaxant with a poorly defined mechanism, likely involving general CNS depression. It does not directly relax skeletal muscle or act at the neuromuscular junction. It is FDA-approved for acute musculoskeletal spasm as an adjunct to rest and physical therapy. Its evidence base is more modest than cyclobenzaprine's, with fewer randomized controlled trials, but it has a favorable safety profile relative to other muscle relaxants.

Dosing and Safety

The initial dose is 1500 mg four times daily for 2-3 days, then reduced to 750 mg four times daily or 1500 mg three times daily. It is available in both oral and injectable formulations. Methocarbamol is less sedating than cyclobenzaprine and carisoprodol and has minimal anticholinergic effects. It may cause benign brown-black urine discoloration, which patients should be warned about. It is not a controlled substance and is available over the counter in Canada and some European countries.

Carisoprodol: Abuse Potential

Mechanism and Concerns

Carisoprodol is metabolized to meprobamate, a Schedule IV controlled substance with barbiturate-like effects. Meprobamate acts at GABA-A receptors, producing anxiolytic, sedative, and euphoric effects. Carisoprodol itself was reclassified as Schedule IV in 2012 (it was previously unscheduled). The half-life of carisoprodol is only 2 hours, but meprobamate persists for 6-17 hours.

Abuse Profile

Carisoprodol has high abuse potential, particularly when combined with opioids and benzodiazepines in what is known as the "Holy Trinity" or "Houston Cocktail." Physical dependence develops with chronic use, and the withdrawal syndrome includes insomnia, tremor, anxiety, and potentially seizures. No major guideline recommends carisoprodol for chronic pain management. Prescribing has declined significantly but remains a concern in some regions. It should be discontinued in patients receiving chronic opioid therapy.

Clinical Pearls

The fundamental clinical distinction is between spasticity and spasm: baclofen and tizanidine are for upper motor neuron spasticity, while cyclobenzaprine and methocarbamol are for peripheral musculoskeletal spasm — they are not interchangeable. Tizanidine requires hepatic monitoring and has a dangerous interaction with CYP1A2 inhibitors, so always check for fluvoxamine and ciprofloxacin before prescribing. Baclofen withdrawal, especially from intrathecal delivery, is a medical emergency that can mimic malignant hyperthermia or neuroleptic malignant syndrome. Cyclobenzaprine at very low doses (1-4 mg at bedtime) may improve sleep in fibromyalgia without causing daytime sedation. Carisoprodol should be avoided in chronic pain management due to its meprobamate metabolite and high abuse potential — methocarbamol is a safer substitute if a muscle relaxant is needed. None of the muscle relaxants have strong evidence supporting use beyond 2-3 weeks for musculoskeletal spasm.

References

1. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365-370.
2. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-175.
3. Reeves RR, Burke RS. Carisoprodol: abuse potential and withdrawal syndrome. Curr Drug Abuse Rev. 2010;3(1):33-38.
4. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004;26(9):1355-1367.

Read this lecture as Markdown